The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
Open accessAbstract
Objective: A protective association between higher vitamin D levels and the onset of multiple sclerosis (MS) has been demonstrated; however, its role in modulating MS clinical course has been little studied. We investigated whether higher levels of serum 25‐hydroxyvitamin D (25‐OH‐D) were associated with a lower risk of relapses in people with MS. Methods: We conducted a prospective cohort study of 145 participants with relapsing‐remitting MS from 2002 to 2005. Serum 25‐OH‐D levels were measured biannually, and the hazard of relapse was assessed using survival analysis. Results: There was an inverse linear relationship between 25‐OH‐D levels and the hazard of relapse over the subsequent 6 months, with hazard ratio (HR) 0.91 (95% confidence interval [CI]: 0.85–0.97) per 10nmol/l increase in 25‐OH‐D level (p= 0.006). When variation due to timing of blood collection was removed by estimating 25‐OH‐D at the start of each season, this association persisted, with HR 0.90 (95% CI, 0.83–0.98) per 10nmol/l increase (p= 0.016). Taking into account the biological half‐life of 25‐OH‐D, we estimated 25‐OH‐D at monthly intervals, resulting in a slightly enhanced association, with HR 0.88 (95% CI, 0.82–0.95) per 10nmol/l increase (p= 0.001). Adjusting for potential confounders did not alter these findings. Interpretation: In this prospective population‐based cohort study, in a cohort largely on immunomodulatory therapy, higher 25‐OH‐D levels were associated with a reduced hazard of relapse. This occurred in a dose‐dependent linear fashion, with each 10nmol/l increase in 25‐OH‐D resulting in up to a 12% reduction in risk of relapse. Clinically, raising 25‐OH‐D levels by 50nmol/l could halve the hazard of a relapse. ANN NEUROL 2010;68:193–203
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
Heaney, R. P., Davies, K. M., Chen, T. C., Holick, M. F., & Barger-Lux, M. J. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.204 · Cited by 1,396
On the regression analysis of multivariate failure time data
PRENTICE, R. L., WILLIAMS, B. J., & PETERSON, A. V. (1981) · Biometrika · doi:10.1093/biomet/68.2.373 · Cited by 1,333
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Vitamin D intake and incidence of multiple sclerosis
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004) · Neurology · doi:10.1212/01.wnl.0000101723.79681.38 · Cited by 1,093
Hathcock, J. N., Shao, A., Vieth, R., & Heaney, R. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.1.6 · Cited by 886
Research works printed but not linked: 3
- 10.1002/1531-8249(200008)48:2<271::AID-ANA28>3.0.CO;2-O · doi:10.1002/1531-8249(200008)48:2<271::aid-ana28>3.0.co;2-o
- 10.1002/ana.1032 · DOI · Paper page
- 10.1038/222482a0 · doi:10.1038/222482a0
Cited by
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., & Taylor, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240432 · Cited by 718
Self-citationVitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 516
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Sintzel, M. B., Rametta, M., & Reder, A. T. (2018) · Neurology and Therapy · doi:10.1007/s40120-017-0086-4 · Cited by 435
Environmental factors in multiple sclerosis
Ascherio, A. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.865866 · Cited by 330
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses
Farez, M. F., Mascanfroni, I. D., Méndez-Huergo, S. P., Yeste, A., Murugaiyan, G., Garo, L. P., Balbuena Aguirre, M. E., Patel, B., Ysrraelit, M. C., Zhu, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.025 · Cited by 318
Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis
Wood, B., van der Mei, I., Ponsonby, A.-L., Pittas, F., Quinn, S., Dwyer, T., Lucas, R., & Taylor, B. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512450351 · Cited by 294
Self-citationThe initiation and prevention of multiple sclerosis
Ascherio, A., Munger, K. L., & Lünemann, J. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.198 · Cited by 289
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis
Mowry, E. M., Waubant, E., McCulloch, C. E., Okuda, D. T., Evangelista, A. A., Lincoln, R. R., Gourraud, P., Brenneman, D., Owen, M. C., Qualley, P., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23591 · Cited by 270
Soilu-Hänninen, M., Åivo, J., Lindström, B.-M., Elovaara, I., Sumelahti, M.-L., Färkkilä, M., Tienari, P., Atula, S., Sarasoja, T., Herrala, L., et al. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301876 · Cited by 269
Vitamin D and multiple sclerosis: An update
Pierrot-Deseilligny, C., & Souberbielle, J.-C. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.03.014 · Cited by 265
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model
Wergeland, S., Torkildsen, Ø., Myhr, K.-M., Aksnes, L., Mørk, S. J., & Bø, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026262 · Cited by 88
“Low serum levels of vitamin D3 has been found in relation to MS relapses [13], and high serum levels of vitamin D3 in MS-patients seem to reduce the hazard ratio for new relapses in a linear relationship [14].”
BackgroundResultBhargava, P., Cassard, S., Steele, S. U., Azevedo, C., Pelletier, D., Sugar, E. A., Waubant, E., & Mowry, E. M. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.10.004 · Cited by 69
Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis
Rolf, L., Damoiseaux, J., Huitinga, I., Kimenai, D., van den Ouweland, J., Hupperts, R., & Smolders, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00263 · Cited by 28
Metadata
- Authors
- Simpson, S., Taylor, B., Blizzard, L., Ponsonby, A., Pittas, F., Tremlett, H., Dwyer, T., Gies, P., & van der Mei, I.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-08
- Volume
- 68
- Issue
- 2
- Pages
- 193-203
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1538563548
- Cited by
- 457
- References
- 40
- FWCI
- 25.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.